Healthcare of Ontario Pension Plan Trust Fund Takes Position in AxoGen, Inc. $AXGN

Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of AxoGen, Inc. (NASDAQ:AXGN) in the 1st quarter, Holdings Channel.com reports. The fund acquired 116,108 shares of the medical equipment provider’s stock, valued at approximately $3,847,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in AXGN. Stephens Investment Management Group LLC acquired a new position in shares of AxoGen during the fourth quarter worth about $5,043,000. Legato Capital Management LLC acquired a new stake in shares of AxoGen during the 4th quarter worth about $1,323,000. SG Americas Securities LLC lifted its stake in AxoGen by 459.9% during the fourth quarter. SG Americas Securities LLC now owns 65,480 shares of the medical equipment provider’s stock worth $2,143,000 after purchasing an additional 53,786 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in AxoGen in the fourth quarter valued at approximately $800,000. Finally, F&V Capital Management LLC purchased a new position in AxoGen in the fourth quarter valued at approximately $5,793,000. 80.29% of the stock is currently owned by institutional investors and hedge funds.

AxoGen Price Performance

Shares of AXGN opened at $41.35 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.33 and a current ratio of 7.10. AxoGen, Inc. has a fifty-two week low of $12.39 and a fifty-two week high of $46.95. The firm has a 50-day simple moving average of $42.10 and a 200-day simple moving average of $37.33. The company has a market capitalization of $2.20 billion, a price-to-earnings ratio of -60.81 and a beta of 1.09.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.12 EPS for the quarter, meeting the consensus estimate of $0.12. AxoGen had a negative return on equity of 10.13% and a negative net margin of 13.36%.The firm had revenue of $69.73 million during the quarter, compared to the consensus estimate of $67.10 million. On average, equities research analysts anticipate that AxoGen, Inc. will post -0.37 earnings per share for the current year.

Insider Activity at AxoGen

In other AxoGen news, Director Amy Mcbride Wendell sold 1,647 shares of the business’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $42.60, for a total value of $70,162.20. Following the transaction, the director directly owned 93,826 shares of the company’s stock, valued at approximately $3,996,987.60. The trade was a 1.73% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Kathy Johnson Weiler sold 16,344 shares of AxoGen stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $44.09, for a total transaction of $720,606.96. Following the completion of the sale, the director directly owned 16,344 shares in the company, valued at approximately $720,606.96. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 29,041 shares of company stock worth $1,268,792 in the last three months. Insiders own 2.44% of the company’s stock.

Wall Street Analysts Forecast Growth

AXGN has been the subject of several research analyst reports. Lake Street Capital upped their target price on shares of AxoGen from $40.00 to $50.00 and gave the company a “buy” rating in a report on Thursday, April 23rd. Citigroup reaffirmed a “market outperform” rating on shares of AxoGen in a report on Thursday. Wells Fargo & Company boosted their target price on AxoGen from $40.00 to $48.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. Zacks Research upgraded AxoGen from a “strong sell” rating to a “hold” rating in a research note on Friday, May 29th. Finally, Wall Street Zen upgraded AxoGen from a “hold” rating to a “buy” rating in a research note on Sunday, July 26th. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $51.00.

AxoGen News Roundup

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: AxoGen raised its 2026 outlook, citing momentum in breast reconstruction and continued demand for its peripheral nerve repair products. The improved outlook suggests management sees stronger revenue potential than previously expected. AxoGen Is Up After Raising 2026 Outlook
• Positive Sentiment: Second-quarter revenue reached $69.73 million, exceeding analyst expectations of $67.10 million. Adjusted earnings of $0.12 per share also topped the Zacks consensus estimate of $0.09 and matched the broader analyst consensus. AxoGen Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: Canaccord Genuity raised its price target from $50 to $55 and reiterated a “buy” rating. Citizens JMP also lifted its target to $55 and maintained a “market outperform” rating, signaling increased confidence in AxoGen’s growth prospects. Analyst Price Target Revisions
• Neutral Sentiment: The earnings report showed strong revenue growth, but conference-call commentary highlighted ongoing margin challenges as AxoGen invests for expansion.
• Negative Sentiment: AxoGen continues to report negative profitability metrics, including a net loss and negative net margin and return on equity. Investors may therefore remain focused on whether the stronger outlook translates into sustainable earnings growth.

AxoGen Company Profile

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.